Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions: May 2010 update.

Autoria(s): Cuisset T.; Valgimigli M.; Mudra H.; Muller O.; Wijns W.; Huber K.
Data(s)

2010
Identificador

http://serval.unil.ch/?id=serval:BIB_C7FA34DF32F1

isbn:1969-6213 (Electronic)

pmid:20542796

doi:10.4244/

isiid:000294134100006
Idioma(s)

en
Fonte

Eurointervention : Journal of Europcr In Collaboration With the Working Group On Interventional Cardiology of the European Society of Cardiology, vol. 6, no. 1, pp. 39-45
Palavras-Chave #Acute Coronary Syndrome/therapy; Aged; Angioplasty, Balloon, Coronary/adverse effects; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Fibrinolytic Agents/administration & dosage; Fibrinolytic Agents/adverse effects; Hemorrhage/chemically induced; Humans; Myocardial Infarction/therapy; Platelet Aggregation Inhibitors/administration & dosage; Platelet Aggregation Inhibitors/adverse effects; Risk Assessment; Thrombosis/etiology; Thrombosis/prevention & control; Time Factors; Treatment Outcome
Tipo

info:eu-repo/semantics/article

article
Acesso ao item digital